Logo image of ENVB

ENVERIC BIOSCIENCES INC (ENVB) Stock Fundamental Analysis

NASDAQ:ENVB - Nasdaq - US29405E4061 - Common Stock - Currency: USD

1.25  -0.02 (-1.57%)

After market: 1.2699 +0.02 (+1.59%)

Fundamental Rating

2

ENVB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While ENVB seems to be doing ok healthwise, there are quite some concerns on its profitability. ENVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ENVB has reported negative net income.
In the past year ENVB has reported a negative cash flow from operations.
In the past 5 years ENVB always reported negative net income.
In the past 5 years ENVB always reported negative operating cash flow.
ENVB Yearly Net Income VS EBIT VS OCF VS FCFENVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

ENVB has a worse Return On Assets (-182.35%) than 89.74% of its industry peers.
With a Return On Equity value of -237.48%, ENVB is not doing good in the industry: 71.79% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -182.35%
ROE -237.48%
ROIC N/A
ROA(3y)-267.33%
ROA(5y)-230.52%
ROE(3y)-532.66%
ROE(5y)-403.62%
ROIC(3y)N/A
ROIC(5y)N/A
ENVB Yearly ROA, ROE, ROICENVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENVB Yearly Profit, Operating, Gross MarginsENVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

6

2. Health

2.1 Basic Checks

ENVB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENVB has more shares outstanding
There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENVB Yearly Shares OutstandingENVB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
ENVB Yearly Total Debt VS Total AssetsENVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -33.30, we must say that ENVB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -33.30, ENVB is not doing good in the industry: 86.15% of the companies in the same industry are doing better.
ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.3
ROIC/WACCN/A
WACCN/A
ENVB Yearly LT Debt VS Equity VS FCFENVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ENVB has a Current Ratio of 4.08. This indicates that ENVB is financially healthy and has no problem in meeting its short term obligations.
ENVB has a Current ratio of 4.08. This is in the better half of the industry: ENVB outperforms 63.08% of its industry peers.
ENVB has a Quick Ratio of 4.08. This indicates that ENVB is financially healthy and has no problem in meeting its short term obligations.
ENVB has a better Quick ratio (4.08) than 64.62% of its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
ENVB Yearly Current Assets VS Current LiabilitesENVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

ENVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.24%, which is quite impressive.
EPS 1Y (TTM)86.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ENVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.88%
EPS Next 2Y38.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENVB Yearly Revenue VS EstimatesENVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2027 2028 2029 2030 2031 50M 100M
ENVB Yearly EPS VS EstimatesENVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ENVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENVB Price Earnings VS Forward Price EarningsENVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENVB Per share dataENVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as ENVB's earnings are expected to grow with 38.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENVB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (6/17/2025, 4:51:48 PM)

After market: 1.2699 +0.02 (+1.59%)

1.25

-0.02 (-1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners14.17%
Inst Owner Change-76.54%
Ins Owners8.99%
Ins Owner Change6.85%
Market Cap3.09M
Analysts82.86
Price Target55.9 (4372%)
Short Float %13.54%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)39.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-21.3
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-3.04
OCFYN/A
SpS0
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.35%
ROE -237.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-267.33%
ROA(5y)-230.52%
ROE(3y)-532.66%
ROE(5y)-403.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -33.3
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.8%
EPS Next Y95.88%
EPS Next 2Y38.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.03%
EBIT Next 3Y2.98%
EBIT Next 5Y33.29%
FCF growth 1Y57.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.62%
OCF growth 3YN/A
OCF growth 5YN/A